Drug facts

How long does tirzepatide take to work?

By David Chen·Editor·Reviewed September 2026

Two clocks, not one²

“Working” means two different things, and they run on different schedules. The drug’s effects on the body begin within days of the first dose. Weight loss, the thing most people mean, accumulates over months. The label covers the first clock; SURMOUNT-1 and its published analyses cover the second.

What the first dose does²

After an injection, tirzepatide reaches its highest concentration in the blood at a median of 24 hours, with a range of 8 to 72 hours. The pharmacodynamics section says it decreases calorie intake, an effect likely mediated by appetite, and that it delays gastric emptying, with the delay largest after the first dose and diminishing over time.

Because the drug is given weekly and clears slowly, each dose adds to what is left of the last. The label reports that steady-state concentrations were reached after 4 weeks of once-weekly dosing. The half-life behind that, and what it means once doses stop, is on how long tirzepatide stays in your system.

The first month is a starting dose¹

The Zepbound label’s dosing section sets out the schedule:

• The recommended starting dosage for all indications is 2.5 mg, injected once weekly for 4 weeks.
• In the label’s words, “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
• After 4 weeks the dose goes to 5 mg, and it may be increased in 2.5 mg steps after at least 4 weeks on the current dose.
• The maintenance doses for weight reduction are 5, 10 or 15 mg; for obstructive sleep apnea, 10 or 15 mg. The maximum is 15 mg.

The label gives the reason for the gradual climb: to reduce the risk of gastrointestinal side effects. The starting dose is there to be tolerated, not to produce the weight result, so the first month is a poor place to judge the drug by. The full schedule is on the dosage chart.

When weight loss showed up³

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight with a weight-related condition, and no diabetes. It ran 72 weeks, the first 20 of them a dose-escalation period. Everyone started at 2.5 mg and stepped up every four weeks; the 5 mg group reached its dose at week 4, the 10 mg group at week 12 and the 15 mg group at week 20.⁴

Each row was measured in a different group, and the differences matter. Week 8 counts 1,775 participants on treatment⁵, all of them by then four weeks into 5 mg. Week 12 counts the 1,545 who took at least three-quarters of their doses.⁴ Week 24 is an average across four starting-BMI groups in 1,438 participants selected for adherence and for going on to lose at least 5%, and the same analysis found weight reduction greatest in the first 24 weeks.⁶ Week 72 is the trial’s own result in everyone randomized, against −3.1% on placebo. The full sequence is laid out on tirzepatide weight loss results, week by week.

Slow starters⁴

Not everyone moved on the same schedule. Of the 1,545 adherent participants analyzed at week 12, 278 (18.0%) had lost less than 5%. The paper calls them late responders, and most of them caught up: 70% had lost 5% or more by week 24 and 90% by week 72. Among those who got there, the average time to reach 5% was 24.8 weeks.

They did not catch up entirely. At week 72 the late responders averaged an 11.0% reduction, against 22.5% for those who had already lost 5% by week 12. The small group that never reached 5% at all, and the plateau that comes later for nearly everyone, are covered in not losing weight on tirzepatide.

Side effects run on the same clock⁷

The same early weeks carry most of the side effects. The label states that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time, and that most people who stopped because of side effects did so in the first few months, because of gastrointestinal reactions. SURMOUNT-1 reported the same pattern: gastrointestinal events occurred primarily during dose escalation.³ The rates by dose are on the side-effects page.

Mounjaro and Zepbound⁸

Both are tirzepatide, and both labels start at 2.5 mg once weekly and step up in 2.5 mg increments after at least 4 weeks on the current dose. What differs is the goal. Mounjaro is approved for type 2 diabetes, and its label ties each increase to whether additional glycemic control is needed. Zepbound is approved for weight reduction and sleep apnea, and the weight checkpoints above come from its obesity trial. “How fast does Mounjaro work” is therefore partly a blood-sugar question, which the weight figures on this page do not answer. How the two brands differ →

What none of this covers

The label leaves the choice of maintenance dose to the prescriber, in its own words: “Consider treatment response and tolerability when selecting the maintenance dosage.”¹ If cost is shaping how long a course lasts, the price index shows what each seller charges as a true calendar month.

Nothing here is medical advice, and this page deliberately suggests no dose, no timeline and no point at which to change course. Those are decisions for the prescriber who knows your history. See the medical disclaimer.